Sorry, you need to enable JavaScript to visit this website.

GREENSTONE LLC INTRODUCES
LINEZOLID TABLETS
Authorized Generic of ZYVOX® (linezolid) tablets

PEAPACK, NJ, December 2015 — Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc (NYSE: PFE), is pleased to announce the introduction of linezolid tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 600 mg x 20 tablets per bottle and 600 mg x unit dose packages of 20 tablets.

Greenstone’s linezolid tablets product is the authorized generic of, and equivalent to the innovator’s product, ZYVOX® (linezolid) tablets. This new authorized generic adds to Greenstone’s consistently growing line of products, and is backed by the distribution and customer service support of Pfizer Inc., one of the world’s premiere biopharmaceutical companies. As a subsidiary of Pfizer, Greenstone operates under the same values and commitment to bring quality authorized generics to customers, payers, and the patients it serves.

See the Full Prescribing Information for Greenstone’s linezolid tablets at http://www.greenstonellc.com/product-list.aspx.

For more information about Greenstone LLC and its products, visit http://greenstonellc.com.

Zyvox is a registered trademark of C.P. Pharmaceuticals International C.V.